[Molecular docking study and experimental evaluation of potential CTLA-4 binding peptides]

Area of Science:

• Immunology
• Computational Chemistry
• Drug Discovery

Background:

• Immune checkpoints like CTLA-4, PD-1, and PD-L1 are targets for cancer immunotherapy.
• Monoclonal antibodies are effective but have clinical limitations.
• Low molecular weight compounds are sought to regulate immune response inhibitors.

Purpose of the Study:

• To investigate the interaction of synthetic peptides with the CTLA-4 molecule.
• To evaluate the potential of these peptides as alternatives to antibodies for immune regulation.

Main Methods:

• Molecular docking simulations were employed to predict peptide-CTLA-4 interactions.
• Mathematical modeling was used to analyze binding at the 99MYPPPY104 loop.
• Specificity was assessed using recombinant chimeric CTLA-4 protein.

Main Results:

• Synthetic peptides were found to interact with the 99MYPPPY104 loop of CTLA-4.
• These peptides demonstrated potential to block the CTLA-4 receptor's interaction with its ligand, B7-1.
• The specificity of peptide interaction with CTLA-4 was confirmed.

Conclusions:

• A synthetic peptide was identified with the potential to modulate CTLA-4 activity.
• This peptide may serve as a basis for developing novel immunomodulatory drugs.
• Potential therapeutic applications include cancer and autoimmune disease treatment.